Skip to main content

Intra-Cellular Therapies, Inc.

ITCIDelisted Apr 2, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001567514

Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Intra-Cellular Therapies, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Intra-Cellular Therapies, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Intra-Cellular Therapies, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Riggs Rory BDirector0Apr 2, 20250
Marcus Joel SDirector0IndirectApr 2, 20250
Van Nostrand Robert LDirector0Apr 2, 20250
Halstead MichaelPresident0Apr 2, 20250
Mates SharonChairman and CEO0IndirectApr 2, 20250
Neumann MarkEVP, Chief Commercial Officer0Apr 2, 20250
Narula SanjeevExecutive Vice President & CFO–Apr 2, 20250
Durgam Suresh K.EVP, Chief Medical Officer0Apr 2, 20250
Salas Eduardo ReneDirector0Apr 2, 20250
Hineline Lawrence J.SVP of Finance, CFO0Mar 11, 20240
Rawlins MichaelDirector–Jun 13, 20220
Lerner Richard ADirector96,663IndirectOct 4, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Feb 22, 2023 (view filing)Feb 211 dayHalstead MichaelEVP and General CounselSSale−11.1K$46.84−$521.7K−100.0%0 after4 lots
Feb 22, 2023 (view filing)Feb 17-215 daysHineline Lawrence J.SVP of Finance CFOSSale−64.4K$49.34−$3.18M−100.0%0 after6 lots
Feb 22, 2023 (view filing)Feb 211 dayMates SharonChairman, President & CEOSSale−27.8K$46.83−$1.30M−2.5%1.10M after4 lots
Dec 21, 2022 (view filing)Dec 192 daysMarcus Joel SDirectorSSale−5.00K$50.82−$254.1K−14.6%29.2K after
Dec 15, 2022 (view filing)Dec 132 daysMates SharonChairman, President & CEOSSale−33.1K$55.00−$1.82M−2.9%1.10M after
Dec 2, 2022 (view filing)Dec 11 dayHalstead MichaelEVP and General CounselSSale−50.0K$53.73−$2.69M−100.0%0 after2 lots
Nov 8, 2022 (view filing)Nov 71 dayMarcus Joel SDirectorSSale−10.0K$52.30−$523.0K−22.6%34.2K after2 lots
Sep 23, 2022 (view filing)Sep 212 daysHineline Lawrence J.SVP of Finance CFOSSale−65.2K$45.63−$2.97M−100.0%0 after2 lots
Aug 12, 2022 (view filing)Aug 111 dayVan Nostrand Robert LDirectorSSale−30.0K$57.13−$1.71M−76.8%9.04K after2 lots
Aug 12, 2022 (view filing)Aug 111 dayMarcus Joel SDirectorSSale−10.0K$59.22−$592.2K−18.4%44.2K after
May 13, 2022 (view filing)May 121 dayMarcus Joel SDirectorSSale−10.0K$55.00−$550.0K−15.6%54.2K after
Apr 8, 2022 (view filing)Apr 8Same dayNeumann MarkEVP, Chief Commercial OfficerSSale−86.3K$64.37−$5.56M−65.6%45.3K after3 lots
Mar 18, 2022 (view filing)Mar 16-182 daysRiggs Rory BDirectorSSale−226.7K$60.11−$13.6M−100.0%0 after6 lots
Mar 9, 2022 (view filing)Mar 7-82 daysMarcus Joel SDirectorSSale−20.0K$53.14−$1.06M−40.8%29.0K after3 lots
Mar 4, 2022 (view filing)Mar 2-42 daysDurgam Suresh K.Chief Medical OfficerSSale−8.04K$56.28−$452.3K−25.8%23.1K after2 lots
Feb 25, 2022 (view filing)Feb 241 dayDurgam Suresh K.Chief Medical OfficerSSale−4.05K$52.27−$211.5K−11.5%31.1K after3 lots
Feb 25, 2022 (view filing)Feb 241 dayNeumann MarkEVP, Chief Commercial OfficerSSale−7.91K$52.21−$412.8K−14.8%45.3K after3 lots
Feb 25, 2022 (view filing)Feb 241 dayHalstead MichaelEVP and General CounselSSale−7.91K$51.98−$410.9K−100.0%0 after2 lots
Feb 25, 2022 (view filing)Feb 241 dayHineline Lawrence J.SVP of Finance CFOSSale−7.45K$51.97−$387.3K−100.0%0 after3 lots
Feb 25, 2022 (view filing)Feb 241 dayMates SharonChairman, President & CEOSSale−22.6K$51.98−$1.17M−2.0%1.09M after3 lots
Feb 23, 2022 (view filing)Feb 221 dayDurgam Suresh K.Chief Medical OfficerSSale−4.18K$55.29−$231.0K−13.3%27.3K after2 lots
Feb 23, 2022 (view filing)Feb 221 dayNeumann MarkEVP, Chief Commercial OfficerSSale−11.1K$55.29−$615.8K−19.7%45.3K after2 lots
Feb 23, 2022 (view filing)Feb 221 dayHalstead MichaelEVP and General CounselSSale−11.1K$55.40−$617.1K−100.0%0 after2 lots
Feb 23, 2022 (view filing)Feb 221 dayHineline Lawrence J.SVP of Finance CFOSSale−10.4K$55.40−$578.5K−100.0%0 after2 lots
Feb 23, 2022 (view filing)Feb 221 dayMates SharonChairman, President & CEOSSale−27.8K$55.39−$1.54M−2.5%1.09M after2 lots
Jan 20, 2022 (view filing)Jan 182 daysDurgam Suresh K.Chief Medical OfficerSSale−6.22K$42.03−$261.6K−21.2%23.1K after
Jan 11, 2022 (view filing)Jan 101 dayDurgam Suresh K.Chief Medical OfficerSSale−6.87K$40.76−$280.0K−19.0%29.3K after3 lots
Jan 11, 2022 (view filing)Jan 101 dayNeumann MarkEVP, Chief Commercial OfficerSSale−20.9K$40.78−$854.3K−31.6%45.3K after3 lots
Jan 11, 2022 (view filing)Jan 101 dayHalstead MichaelEVP and General CounselSSale−19.6K$40.77−$800.8K−100.0%0 after3 lots
Jan 11, 2022 (view filing)Jan 101 dayHineline Lawrence J.SVP of Finance CFOSSale−19.6K$40.76−$800.4K−100.0%0 after3 lots
Jan 11, 2022 (view filing)Jan 101 dayMates SharonChairman, President & CEOSSale−41.9K$40.78−$1.71M−3.7%1.09M after3 lots
Dec 23, 2021 (view filing)Dec 212 daysHalstead MichaelEVP and General CounselSSale−176.9K$47.56−$8.41M−100.0%0 after5 lots
Dec 23, 2021 (view filing)Dec 212 daysHineline Lawrence J.SVP of Finance CFOSSale−175.0K$47.59−$8.33M−100.0%0 after6 lots
Oct 19, 2021 (view filing)Oct 181 dayNeumann MarkEVP, Chief Commercial OfficerSSale−13.4K$40.86−$549.6K−22.9%45.3K after4 lots
Oct 18, 2021 (view filing)Oct 14-184 daysMates SharonChairman, President & CEOSSale−50.0K$40.00−$2.00M−4.4%1.09M after3 lots